Learn more about our Advocacy work.
WASHINGTON, D.C.—AdvaMed, the MedTech Association®, is among 67 stakeholder groups, including patient advocacy groups and state medtech and life sciences associations, urging the Centers for Medicare and Medicaid Services (CMS)…
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
WASHINGTON, D.C.—AdvaMed, the MedTech Association®, today welcomed the kickoff of the latest Medical Device User Fee Amendments (MDUFA) discussion at a public meeting at FDA headquarters. ThreeAdvaMed® senior staff members…
AdvaMed, the MedTech Association®, released the following statement today from Shaye Mandle, executive director of the organization’s Digital Health Tech division, on the announcement from the White House, CMS, and…
WASHINGTON, D.C. – In a new op-ed in The Washington Times, Scott Whitaker, president and CEO of AdvaMed, the MedTech Association®, laid out medtech’s vital role in the Trump administration’s…
WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the MedTech Association®, issued the following statement on the White House’s “America’s AI Action Plan”:
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.
AdvaMed® submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.
JoinAdvaMed® and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.
WASHINGTON – Today, AdvaMed, the MedTech Association®, released the following statement from President and CEO Scott Whitaker on the impact the “One Big Beautiful Bill Act” will have on medtech…